Medication info
Linadip Duo Tablets 2.5/850 mg (Linagliptin, Metformin)

Linadip Duo Tablets 2.5/850 mg (Linagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Huons Co., Ltd.
Appearance
Light orange, oval-shaped, double-convex film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201901611 · Approved 2019.03.18 · Insurance code 670609250

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients who do not achieve adequate glycemic control with metformin monotherapy: The initial dose of this medicine should include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient’s current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current metformin dose. When this medicine is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). 5. Patients who do not achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current metformin dose. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral glucose-lowering agent. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in Whom the Medicine Must Not Be Used).

Ingredients

Manufacturer
Huons Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication aids patients with type 2 diabetes who need to take both linagliptin and metformin to achieve better blood sugar control. It supports blood sugar management during dietary adjustments and exercise regimens. Therefore, it is effective in maintaining stable blood sugar levels. If taken consistently according to the patient's health status, it helps improve blood sugar control.

How to take

Adult dose

The dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients who do not achieve adequate glycemic control with metformin monotherapy: The initial dose of this medicine should include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient’s current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current metformin dose. When this medicine is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). 5. Patients who do not achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current metformin dose. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral glucose-lowering agent. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in Whom the Medicine Must Not Be Used).

Precautions

This medication contains the two ingredients, metformin and linagliptin. It is important to note that serious side effects, such as lactic acidosis, may occur while taking this medication, especially in patients with poor kidney function, liver problems, congestive heart failure, or acute myocardial infarction. Additionally, patients with allergies to any component of this medication or any other ingredients should not take it. There is a risk of hypoglycemia, so blood sugar must be monitored closely, particularly when taken in conjunction with insulin or sulfonylureas. Patients with decreased renal function should undergo regular renal function tests before taking this medication, and if renal function drops below a certain level, it should be avoided. If acute illnesses, severe infections, dehydration, or severe trauma lead to a rapid decline in renal function, this medication should be temporarily discontinued. Rare side effects such as acute pancreatitis or bullous pemphigoid may occur, so if severe abdominal pain or skin blisters develop during treatment, healthcare providers should be notified immediately. This medication can lower vitamin B12 levels, so long-term users should be tested for vitamin B12 deficiency and receive supplementation if necessary. Pregnant women or those who might become pregnant, as well as breastfeeding women, should ideally avoid this medication. Safety and efficacy in children and adolescents have not been established, so it is not recommended for children under 10 years of age or adolescents aged 10 to 17. Elderly patients who frequently have impaired renal function should have their kidney function monitored regularly while taking this medication, and doses should be adjusted accordingly. This medication may increase the risk of lactic acidosis when taken with alcohol, so it is advisable to avoid drinking. Before and after tests using radiocontrast iodine agents, the use of this medication should be temporarily suspended, and it should be resumed only after renal function has stabilized. If surgery is planned, the medication should be stopped 48 hours prior and resumed once renal function improves post-surgery. This medication can interact with various other drugs, so patients taking other medications must inform their doctor or pharmacist. In cases of overdose, serious side effects such as lactic acidosis may occur, and immediate medical attention should be sought.

Side effects

  • Lactic acidosis
  • decreased and deficiency of vitamin B12
  • hypoglycemia
  • taste disorders
  • cough
  • decreased appetite
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
Show 153 more
  • vomiting
  • abdominal pain
  • ulcer formation in the mouth
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • blistering pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • constipation
  • upper abdominal pain
  • enterocolitis
  • bowel obstruction
  • gastroenteritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorders
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • viral upper respiratory infection
  • upper respiratory infection
  • gastroenteritis
  • shingles
  • cystitis
  • hypercholesterolemia
  • inadequate control of diabetes
  • malnutrition
  • hyponatremia
  • drowsiness
  • chest discomfort
  • asthenia
  • epistaxis
  • oropharyngeal pain
  • voice disorders
  • rhinorrhea
  • pulmonary mass
  • arthralgia
  • osteoporosis
  • arthropathy
  • musculoskeletal discomfort
  • myositis
  • myalgia
  • soft tissue mass
  • rotator cuff syndrome
  • increased triglycerides in the blood
  • increased urine albumin/creatinine ratio
  • positive urine leukocytes
  • decreased hemoglobin
  • increased blood potassium
  • increased blood creatinine
  • increased blood creatine phosphokinase
  • increased ALT
  • increased blood triglycerides
  • androgenetic alopecia
  • diabetic foot
  • hyperhidrosis
  • hair loss
  • dermatitis
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • laceration
  • palpitations
  • dry eye
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • stress urinary incontinence
  • hematuria
  • hypotension
  • flushing
  • hepatic steatosis
  • cholelithiasis
  • hearing loss
  • erectile dysfunction
  • goiter
  • anemia
  • dizziness
  • chest pain
  • fever
  • osteoarthritis
  • limb pain
  • pruritus
  • hypertension
  • benign prostatic hyperplasia
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • confusion state
  • nocturia
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. It is best to keep the storage temperature between 1 to 30 degrees Celsius at room temperature to maintain its efficacy over time.

Appearance and packaging

Appearance

Light orange, oval-shaped, double-convex film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.